-
Some On Wall Street Still Back Valeant
Tuesday, March 15, 2016 - 11:51am | 558Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged 40 percent and touched a new 52-week low after the company reported a loss for its fourth quarter and slashed its outlook. The company cited incremental headwinds in Ophthalmology Rx, as well as the Commonwealth and Western Europe businesses...
-
Valeant Has More Volatility Coming, JPMorgan Says
Monday, February 29, 2016 - 12:51pm | 261Read More...JPMorgan recently issued a company note on Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after the company postponed their earnings call and withdrew their prior 2016 financial guidance. Currently, analysts at JPMorgan rate Valeant Pharmaceuticals as Overweight, while a price target is unavailable...
-
Pfizer, Allergan In 'Final Innings' Of Merger Talks
Thursday, November 19, 2015 - 10:41am | 385Read More...Shares of Allergan PLC (NYSE: AGN) and Pfizer Inc. (NYSE: PFE) were both trading lower by nearly 2 percent early Thursday morning. CNBC, citing sources, said the two companies are in the "final stages" of discussions to merge. CNBC added that it is expected to be an all-stock...
-
Time To Buy Mylan's Clear Path To EPS Upside, JP Morgan Says
Wednesday, November 18, 2015 - 11:22am | 303Read More...The share price of Mylan NV (NASDAQ: MYL) has declined 10.51 percent since November 12, when the stock stood at $43.20 at market close. JP Morgan’s Chris Schott has reinitiated coverage of the company with an Overweight rating and a price target of $62. Schott believes that there...
-
How Allergan Could Be Pfizer's Rocket Ship
Thursday, October 29, 2015 - 12:19pm | 583Read More...Pfizer Inc. (NYSE: PFE) confirmed media reports that the company is in talks with Allergan PLC (NYSE: AGN) over a potential business combination transaction. Pfizer said it is in "preliminary friendly discussions" with Allergan, but offered no assurances that the conversations will...
-
Wall Street Defends AbbVie, Says Reaction Is Overdone
Friday, October 23, 2015 - 9:07am | 507Read More...Shares of AbbVie Inc (NYSE: ABBV) plunged more than 10 percent on Thursday, hitting a new 52-week low of $45.45. The FDA requested that the company update its HCV treatment Viekira's label to reflect several cases of liver injury. Matthew Harrison of Morgan Stanley and Chris Schott of...
-
Calls Of Note: The Street's Research Moving Stocks This Monday
Monday, August 3, 2015 - 10:24am | 948Read More...The following represents a hand-picked selection of notable research curated by an analyst known in some circles as "The Sith Overlord Of The Street." RBC: Slashing LinnCo Price Target Last week, John Ragozzino of RBC Capital Markets downgraded shares of LinnCo LLC (NASDAQ: LNCO) to Sector Perform...
-
Analyst Finds Perrigo 'Still Attractive' As Take Out Target
Wednesday, April 22, 2015 - 11:59am | 248Read More...Despite Perrigo Company plc Ordinary Shares (NYSE: PRGO)'s rejection of a $205 a share offer, the company remains an attractive takeover target, an analyst said Wednesday. "Either now or in the future, we can't rule out broader strategic interest in Perrigo," said J.P. Morgan...
-
JPMorgan Says Mylan Has 3 Paths To Upside
Wednesday, April 8, 2015 - 11:04am | 420Read More...In a report published Wednesday, JPMorgan analyst Chris Schott shared his thoughts on Mylan NV (NASDAQ: MYL). According to Schott, Mylan shares are showing an "increasingly attractive" set-up with solid organic growth prospects (12 percent earnings per share compounded annual growth...
-
Will Actavis Win Competition For Allergan's Affection?
Thursday, October 16, 2014 - 11:10am | 839Read More...Four pharmaceutical companies have been flirting with merger deals. Discussing the confusing courting, Barron’s called them the Bob & Carol & Ted & Alice of pharmaceuticals, referencing the sexy 1969 comedy-drama with the tag line “Consider the Possibilities.” In...
-
Pfizer Inc. Is Kicking The Tires At Actavis PLC
Tuesday, September 23, 2014 - 2:45pm | 242Read More...Pfizer Inc. (NYSE: PFE) is interested in buying Actavis PLC (NYSE: ACT), according to unnamed sources cited by Bloomberg news service. Pfizer, whose share price is down more than 6 percent since March, could engineer a tax inversion by acquiring Ireland-based Actavis. AstraZeneca plc (NYSE:...
-
UPDATE: JP Morgan Upgrades Teva Pharmaceuticals
Friday, March 14, 2014 - 12:11pm | 96Read More...On Friday, JP Morgan upgraded shares of Teva Pharmaceuticals (NYSE: TEVA) from Underweight to Neutral and raised the profit target to $49. Analyst Chris Schott is encouraged by “favorable initial Copaxone 3x weekly trends and the potential for additional cost cutting activity,” but remains “less...
-
UPDATE: J.P. Morgan Downgrades Teva Pharmaceutical on Too Much Uncertainty Following CEO Departure
Monday, November 4, 2013 - 11:21am | 163Read More...In a report published Monday, J.P. Morgan analyst Chris Schott downgraded the rating on Teva Pharmaceutical (NYSE: TEVA) from Neutral to Underweight, and lowered the price target from $43.00 to $38.00. In the report, J.P. Morgan noted, “We are downgrading TEVA shares to Underweight from Neutral...
-
UPDATE: J.P. Morgan Upgrades Bristol-Myers Squibb Ahead of Multiple Important Catalysts
Monday, September 16, 2013 - 9:34am | 149Read More...In a report published Monday, J.P. Morgan analyst Chris Schott upgraded the rating on Bristol-Myers Squibb Co. (NYSE: BMY) from Neutral to Overweight, and raised the price target from $50.00 to $52.00. In the report, J.P. Morgan noted, “With Bristol shares having pulled back over the past several...
-
UPDATE: J.P. Morgan Downgrades Teva, Says No Near-Term Upside in Sight
Friday, September 13, 2013 - 11:30am | 139Read More...J.P. Morgan analyst, Chris Schott downgraded Teva Pharmaceuticals (NASDAQ: TEVA) shares from Overweight to Neutral and lowered the December 2014 PT from $45.00 to $43.00. Schott noted that recovery for Teva will be gradual and long-term growth with their cost cutting plan of “$1.5-$2.0 billion...
